Scientists have discovered a potential therapy for cystic fibrosis (CF) patients who are infected with Mycobacterium abscessus, a bacterium that…
Articles by Steve Bryson, PhD
A personalized inhaled phage therapy targeting multidrug-resistant lung infections significantly reduces bacterial load and improves lung function in adults with…
Ivacaftor, a component of the triple-combination therapy Trikafta, is essential to restore mucus clearance in people with…
Metered-dose inhalers that use potent greenhouse gases to propel medicines into the lungs of people with cystic fibrosis (CF)…
At least three months of Kaftrio treatment reduced liver stiffness, an indicator of liver fibrosis, in school-age children and adolescents…
Long-term Trikafta treatment led to improved lung function, fewer respiratory symptoms, and lower sweat chloride levels — elevated…
The European Commission has approved a label expansion for Kaftrio in combination with Kalydeco (ivacaftor) to treat…
Evidence of immune dysfunction — elevated levels of immune cells and immune-related molecules — were found in the lungs of…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Porosome Therapeutics’ new treatment strategy for…
Nearly 80% of men with cystic fibrosis (CF) who underwent fertility treatment due to a lack of sperm became…